top of page
November 15, 2022
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
November 10, 2022
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
September 22, 2022
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
August 12, 2022
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
August 2, 2022
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
June 29, 2022
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
April 27, 2022
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2022
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
March 29, 2022
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings
March 9, 2022
Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum
February 28, 2022
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
February 14, 2022
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
February 8, 2022
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
bottom of page